The Challenge of Applications of Probiotics in Gastrointestinal Diseases

Abstract

Gastrointestinal disease is characterized by gastrointestinal dysfunction with dysbiosis of the microbiome. Probiotics may act as biological agents in treating gastrointestinal diseases through modifying gut microbiota. However, several challenges, including safety, stress resistance, postcolonization quantification, and evaluation models, may hinder the application of probiotics in gastrointestinal diseases. This review introduces the emerging methods for delivering probiotics as well as available materials. Furthermore, we elucidated bacteriocins and their role in helping probiotics obtain a competitive advantage over other strains and challenges of large-scale application. Bacteriocins produced by probiotics also showed promising efficacy in gastrointestinal diseases including the capacity of immune stimulation, intestinal barrier protection, and cytotoxicity against intestinal tumorigenesis. For the quantification of probiotics in complex microbiomes and evaluation methods of probiotic encapsulated delivery systems, recent fluorescent labeling technology and various in vitro and in vivo models were also reviewed. Given the widespread use of probiotic agents in the microecological therapy of gastrointestinal diseases, further understanding of the multiple challenges of probiotic application and the updated methods to improve the colonization and evaluation system of probiotics is of great significance for probiotics as live biotherapeutics.

Molecular identification of bacteria (Klebsiella aerogenes, PP335235) isolated from street food (Fried Rice); study of its antibiotic sensitivity pattern and probiotic fortification of fruit juice (Fragaria ananassa, Passiflora ligularis and Phyllanthus e

“…Probiotics, which are beneficial bacteria, offer a promising alternative to antibiotics in resolving issues caused by several street food pathogens. Unlike antibiotics, probiotics target specific pathogens while preserving the overall gut flora, thereby reducing the risk of antibiotic resistance and supporting quicker recovery from foodborne illnesses [9].…”

Role of tumor-associated macrophages in common digestive system malignant tumors

“…Many digestive system malignant tumors have high incidence and mortality rate, including esophageal cancer (EC), gastric cancer (GC), colorectal cancer (CRC), pancreatic cancer (PC), and liver cancer (LC). There is increasing evidence that the tumor microenvironment (TME), which encompasses the tumor tissue structure comprising stromal cells, is involved in cancer initiation and tumor progression[ 1 - 4 ]. Tumor-associated macrophages (TAMs) as a predominant constituent of the TME, are a special type of macrophages generated by circulating monocytes and recruited into the TME[ 5 ].…”

Metabolomics in viral hepatitis: advances and review

“…As the body’s primary metabolic organ, the liver will inevitably change the linked metabolic network once sickness arises, which will have an impact on the levels of many endogenous small molecule metabolites in the body. The detection of these endogenous small molecules in tissues or fluids can be used as sensitive indicators of liver injury and can aid in the analysis and understanding of the etiology and pathogenesis of liver diseases ( Xiang et al., 2022 ; Wolfe et al., 2023 ).…”